Laurus Labs Ltd (LAUL)

Currency in INR
2,424.00
+24.00(+1.00%)
Closed·
LAURUSLABS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2,394.002,446.90
52 wk Range
917.952,488.00
Key Statistics
Bid/Ask
2,423.90 / 2,424.00
Prev. Close
2,424
Open
2,400
Day's Range
2,394-2,446.9
52 wk Range
917.95-2,488
Volume
2.28M
Average Volume (3m)
2.53M
1-Year Change
142.6426%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LAURUSLABS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2,156.29
Downside
-11.04%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Laurus Labs Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

Analyst Ratings

8 Buy
3 Hold
4 Sell
Ratings:
15 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 2,156.29
(-11.04% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citi
Hold1,720.00-29.04%875.00Upgrade27-07-2026
Citi
Sell875.00-63.90%730.00Maintain08-06-2026
Jefferies
Hold1,060.00-56.27%830.00Upgrade26-01-2026
Kotak
Sell680.00-71.95%625.00Maintain26-01-2026
Jefferies
Sell830.00-65.76%700.00Maintain09-01-2026

Laurus Labs Ltd Earnings Call Summary for Q2/2027

  • Laurus Labs reported record Q2 FY27 revenue of INR 2,206 crores with EBITDA margin expanding to 34.5%; shares rose 2.85% to 52-week high.
  • Small molecule CDMO sales surged 86% YoY; H1 FY27 operating income climbed 31% to INR 4,233 crores with ROCE improving to 22.5% from 17.7%.
  • Management maintains guidance of 60%+ gross margins and 30%+ EBITDA margins; plans INR 3,000 crores CapEx across FY27-FY28 for capacity expansion.
  • Commercial peptide facility commissioned in Q2; revenue expected around 2029. KRKA JV validations begin mid-2027 with revenue in FY28-FY29.
  • Net debt fell to INR 2,466 crores with debt-to-EBITDA at 1.02, though operating cash flow declined 26% in H1 due to inventory buildup.
Last Updated: 29-10-2026, 06:28 pm
Read Full Transcript

Earnings

Latest Release
29-10-2026
EPS / Forecast
8.20 / 6.66
Revenue / Forecast
22.06B / 20.83B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 24.82
Dividend Yield
0.09%
Industry Median 0.64%
Annualised payout
2.20
Paid annually
5-Years Growth
+1.92%
Growth Streak

LAURUSLABS Income Statement

Compare LAURUSLABS to Peers and Sector

Metrics to compare
LAURUSLABS
Peers
Sector
Relationship
P/E Ratio
97.7x32.5x−0.2x
PEG Ratio
1.020.810.00
Price/Book
21.6x4.5x2.6x
Price / LTM Sales
16.7x4.0x2.8x
Upside (Analyst Target)
−11.0%11.1%65.0%
Fair Value Upside
Unlock0.0%9.6%Unlock

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Employees
7059
Market
India

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
144.10M26.67%349.30B
Other Institutional Investors
35.18M6.51%85.27B
Public Companies & Retail Investors
361.03M66.82%875.14B
Total
540.31M100.00%1.31T

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Capital Research and Management Company4.77%2,57,68,7886,24,63,542
Mirae Asset Global Investments Co., Ltd.4.02%2,17,37,4645,26,91,613

FAQ

What Is the Laurus Labs (LAURUSLABS) Share Price Today?

The Laurus Labs share price today is 2,424.00.

What is the current Laurus Labs (LAURUSLABS) share price and day range?

As of 14-11-2026, the Laurus Labs share price is 2,424.00, with a previous close of 2,424.00. The share price has ranged from 2,394.00 to 2,446.90 today, while the 52-week range spans from 917.95 to 2,488.00.

What Is the Laurus Labs Market Cap?

As of today, Laurus Labs market cap is 1.31T.

Does Laurus Labs Pay Dividends? What's The Current Dividend Yield?

The Laurus Labs dividend yield is 0.1%%.

What Is the Laurus Labs (LAURUSLABS) Share Price Target?

The average 12-month share price target for Laurus Labs is 2,156.29, with a high estimate of 2830 and a low estimate of 900. 8 analysts recommend buying, while 4 suggest selling, with an overall rating of Neutral and -11.04% Downside potential.

What Is Laurus Labs's Earnings Per Share (TTM)?

The Laurus Labs EPS (TTM) is 24.82.

When Is the Next Laurus Labs Earnings Date?

Laurus Labs will release its next earnings report on 28-01-2027.

From a Technical Analysis Perspective, Is LAURUSLABS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

What Stock Exchange Does Laurus Labs Trade On?

Laurus Labs is listed and trades on the India National Stock Exchange.

What Is the Stock Symbol for Laurus Labs?

The stock symbol for Laurus Labs is "LAURUSLABS."

How Many Times Has Laurus Labs Stock Split?

Laurus Labs has split 1 times.

How Many Employees Does Laurus Labs Have?

Laurus Labs has 7059 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.